Sukesh Voruganti

1.2k total citations
21 papers, 862 citations indexed

About

Sukesh Voruganti is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Sukesh Voruganti has authored 21 papers receiving a total of 862 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 12 papers in Oncology and 8 papers in Cancer Research. Recurrent topics in Sukesh Voruganti's work include Cancer-related Molecular Pathways (10 papers), Bioactive Compounds and Antitumor Agents (3 papers) and Epigenetics and DNA Methylation (3 papers). Sukesh Voruganti is often cited by papers focused on Cancer-related Molecular Pathways (10 papers), Bioactive Compounds and Antitumor Agents (3 papers) and Epigenetics and DNA Methylation (3 papers). Sukesh Voruganti collaborates with scholars based in United States and China. Sukesh Voruganti's co-authors include Jiang‐Jiang Qin, Ruiwen Zhang, Subhasree Nag, Ming‐Hai Wang, Jianwei Zhou, Hui Wang, Wei Wang, Wei Wang, Weidong Zhang and Wei Wang and has published in prestigious journals such as Nature Communications, Gastroenterology and PLoS ONE.

In The Last Decade

Sukesh Voruganti

21 papers receiving 854 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sukesh Voruganti United States 17 593 326 167 69 66 21 862
Harry A. Rogoff United States 13 746 1.3× 525 1.6× 243 1.5× 62 0.9× 54 0.8× 21 1.1k
Eiji Kobayashi Japan 15 589 1.0× 237 0.7× 95 0.6× 49 0.7× 189 2.9× 36 961
Baoxu Pang Netherlands 12 710 1.2× 232 0.7× 108 0.6× 23 0.3× 54 0.8× 16 1000
Meghan Leary United States 6 797 1.3× 360 1.1× 316 1.9× 33 0.5× 30 0.5× 8 1.2k
Schammim Ray Amith Canada 19 734 1.2× 138 0.4× 171 1.0× 35 0.5× 77 1.2× 20 1.1k
Tessy Thomas Maliekal India 14 506 0.9× 210 0.6× 234 1.4× 23 0.3× 25 0.4× 25 760
Н. А. Попова Russia 18 430 0.7× 234 0.7× 148 0.9× 19 0.3× 67 1.0× 77 793
Sarah Shirley France 12 659 1.1× 168 0.5× 145 0.9× 30 0.4× 24 0.4× 17 853
Andrei P. Komarov United States 9 524 0.9× 207 0.6× 71 0.4× 19 0.3× 42 0.6× 9 690
Yui Yamashita Japan 21 922 1.6× 132 0.4× 141 0.8× 50 0.7× 111 1.7× 46 1.3k

Countries citing papers authored by Sukesh Voruganti

Since Specialization
Citations

This map shows the geographic impact of Sukesh Voruganti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sukesh Voruganti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sukesh Voruganti more than expected).

Fields of papers citing papers by Sukesh Voruganti

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sukesh Voruganti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sukesh Voruganti. The network helps show where Sukesh Voruganti may publish in the future.

Co-authorship network of co-authors of Sukesh Voruganti

This figure shows the co-authorship network connecting the top 25 collaborators of Sukesh Voruganti. A scholar is included among the top collaborators of Sukesh Voruganti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sukesh Voruganti. Sukesh Voruganti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Williams, Noelle S., Stephen S. Gonzales, Jacinth Naidoo, et al.. (2020). Tumor-Activated Benzothiazole Inhibitors of Stearoyl-CoA Desaturase. Journal of Medicinal Chemistry. 63(17). 9773–9786. 12 indexed citations
2.
Wang, Wei, Jiang‐Jiang Qin, Sukesh Voruganti, et al.. (2018). Discovery and Characterization of Dual Inhibitors of MDM2 and NFAT1 for Pancreatic Cancer Therapy. Cancer Research. 78(19). 5656–5667. 42 indexed citations
3.
Qin, Jiang‐Jiang, et al.. (2016). Inulanolide A as a new dual inhibitor of NFAT1-MDM2 pathway for breast cancer therapy. Oncotarget. 7(22). 32566–32578. 24 indexed citations
4.
Yu, Junxian, Sukesh Voruganti, Dandan Li, et al.. (2015). Development and validation of an HPLC-MS/MS analytical method for quantitative analysis of TCBA-TPQ, a novel anticancer makaluvamine analog, and application in a pharmacokinetic study in rats. Chinese Journal of Natural Medicines. 13(7). 554–560. 3 indexed citations
5.
Wang, Wei, Jiang‐Jiang Qin, Sukesh Voruganti, et al.. (2015). Polycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic Implications. Medicinal Research Reviews. 35(6). 1220–1267. 84 indexed citations
6.
Voruganti, Sukesh, Fangxiu Xu, Jiang‐Jiang Qin, et al.. (2015). RYBP predicts survival of patients with non-small cell lung cancer and regulates tumor cell growth and the response to chemotherapy. Cancer Letters. 369(2). 386–395. 24 indexed citations
7.
Qin, Jiang‐Jiang, Wei Wang, Sukesh Voruganti, et al.. (2015). Inhibiting NFAT1 for breast cancer therapy: New insights into the mechanism of action of MDM2 inhibitor JapA. Oncotarget. 6(32). 33106–33119. 26 indexed citations
8.
9.
Wang, Wei, Jiang‐Jiang Qin, Sukesh Voruganti, et al.. (2014). The pyrido[b]indole MDM2 inhibitor SP-141 exerts potent therapeutic effects in breast cancer models. Nature Communications. 5(1). 5086–5086. 81 indexed citations
10.
Wang, Wei, Jiang‐Jiang Qin, Sukesh Voruganti, et al.. (2014). Identification of a New Class of MDM2 Inhibitor That Inhibits Growth of Orthotopic Pancreatic Tumors in Mice. Gastroenterology. 147(4). 893–902.e2. 71 indexed citations
11.
Nag, Subhasree, Jiang‐Jiang Qin, Sukesh Voruganti, et al.. (2014). Development and validation of a rapid HPLC method for quantitation of SP‐141, a novel pyrido[b]indole anticancer agent, and an initial pharmacokinetic study in mice. Biomedical Chromatography. 29(5). 654–663. 12 indexed citations
12.
Qin, Jiang‐Jiang, Wei Wang, Sukesh Voruganti, et al.. (2014). Identification of a new class of natural product MDM2 inhibitor:In vitroandin vivoanti-breast cancer activities and target validation. Oncotarget. 6(5). 2623–2640. 51 indexed citations
13.
Wang, Wei, Jianwen Cheng, Jiang‐Jiang Qin, et al.. (2014). RYBP expression is associated with better survival of patients with hepatocellular carcinoma (HCC) and responsiveness to chemotherapy of HCC cells in vitro and in vivo. Oncotarget. 5(22). 11604–11619. 45 indexed citations
14.
Qian, Biyun, Subhasree Nag, Sukesh Voruganti, et al.. (2013). miRNAs in Cancer Prevention and Treatment and as Molecular Targets for Natural Product Anticancer Agents. Current Cancer Drug Targets. 13(5). 519–541. 26 indexed citations
15.
Qin, Jiang‐Jiang, Hui‐Zi Jin, Ying Huang, et al.. (2013). Selective cytotoxicity, inhibition of cell cycle progression, and induction of apoptosis in human breast cancer cells by sesquiterpenoids from Inula lineariifolia Turcz.. European Journal of Medicinal Chemistry. 68. 473–481. 39 indexed citations
16.
Cox, Laura A., Anthony G. Comuzzie, Lorena M. Havill, et al.. (2013). Baboons as a Model to Study Genetics and Epigenetics of Human Disease. ILAR Journal. 54(2). 106–121. 78 indexed citations
17.
Nag, Subhasree, Jiang‐Jiang Qin, Sukesh Voruganti, et al.. (2012). Anticancer Activity and Molecular Mechanisms of Action of Makaluvamines and Analogues. 4(2). 69–81. 7 indexed citations
18.
Qin, Jiang‐Jiang, et al.. (2012). Natural Product MDM2 Inhibitors: Anticancer Activity and Mechanisms of Action. Current Medicinal Chemistry. 19(33). 5705–5725. 49 indexed citations
19.
Wang, Wei, Xu Zhang, Jiang‐Jiang Qin, et al.. (2012). Natural Product Ginsenoside 25-OCH3-PPD Inhibits Breast Cancer Growth and Metastasis through Down-Regulating MDM2. PLoS ONE. 7(7). e41586–e41586. 76 indexed citations
20.
Zhang, Xiangrong, Hongxia Xu, Xu Zhang, et al.. (2012). Preclinical Evaluation of Anticancer Efficacy and Pharmacological Properties of FBA-TPQ, a Novel Synthetic Makaluvamine Analog. Marine Drugs. 10(5). 1138–1155. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Harry A. Rogoff Breakdown of academic impact, for papers by Eiji Kobayashi Breakdown of academic impact, for papers by Baoxu Pang Breakdown of academic impact, for papers by Meghan Leary Breakdown of academic impact, for papers by Schammim Ray Amith Breakdown of academic impact, for papers by Tessy Thomas Maliekal Breakdown of academic impact, for papers by Н. А. Попова Breakdown of academic impact, for papers by Sarah Shirley Breakdown of academic impact, for papers by Andrei P. Komarov Breakdown of academic impact, for papers by Yui Yamashita
Rankless by CCL
2026